Management of Psoriasis During the Coronavirus Disease 2019 Pandemic

Kathryn Jayne Tan, Maria Rosa Noliza Encarnacion, Olga Marushchak, Rina Anvekar

Research output: Contribution to journalReview articlepeer-review


Coronavirus disease 2019 (COVID-19) was first reported in late December 2019 and, since then, has rapidly taken over the globe, with the scientific world furiously working to gather more data on its eff ect on people with and without concurrent conditions. The dysregulation of the immune system noted in COVID-19 patients is said to be similar to that seen with psoriasis. The pandemic has a_ ected the management of psoriasis, not only for those under treatment but also those about to begin a new therapy. There has been an increasing number of studies in the current literature focusing on the relationship between psoriasis and COVID-19, offering different perspectives. This is a summary of available data in PubMed supplemented by a manual review of reference lists of included articles. There may be lack of robust evidence to drive approaches to the management of psoriasis during the pandemic; however, we hope that the current literature may provide some clues for safety considerations. The conclusion of this article is that each approach to treatment should be personalized, weighing the benefits and risks in each case separately.

Original languageEnglish
Pages (from-to)41-44
Number of pages4
JournalJournal of Clinical and Aesthetic Dermatology
Issue number9
StatePublished - 1 Sep 2021


  • COVID-19
  • Psoriasis
  • biologics
  • immunosuppressant
  • treatment


Dive into the research topics of 'Management of Psoriasis During the Coronavirus Disease 2019 Pandemic'. Together they form a unique fingerprint.

Cite this